Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Learn more

  • Federal contracts (SAM.gov)The Ultimate Guide to SAM.gov Registration
  • Healthcare RFPsHealthcare and Medical Services Bids and Bidding Guide
  • How to answer an RFQRFQ Meaning: What Is an RFQ?
More healthcare and medical services bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Closed bids
  3. ›Federal
  4. ›Q301--Blood Assays for Alzheimer's

U.S. Department Of Veterans Affairs·Pennsylvania

Q301--Blood Assays for Alzheimer's

Closes 6/17/2026$100k – $500kRequest for Quotation
Bid source

This opportunity has closed.

Bid Banana tracks 1.6M+ bids and awards across all 50 states. Save a search and we'll email your new matches, daily or weekly — so the next one reaches you with time to bid.

Get alerted next time

Description

The purpose of this amendment is to extend the due date for quotes for the Q301--Blood Assays for Alzheimer's solicitation. The solicitation is for blood assays related to Alzheimer's disease, but the document does not provide detailed information about the job's work and scope-of-work. The contract is administered by the Veterans Health Administration, Regional Procurement Office East. Key points to consider include: * The due date for quotes has been extended to 06-17-2026 10:00 EDT. * The solicitation is for a specific product or service related to blood assays for Alzheimer's disease. * The contract is with the Veterans Health Administration, which may have specific requirements and regulations. * The primary contact for the solicitation is Renee Kale, Contracting Officer. Some key points to consider when evaluating this opportunity include: • The scope of work and requirements for the blood assays. • The experience and qualifications required for the contract. • The budget and pricing for the contract. • The timeline and deadlines for the contract. • The specific requirements and regulations of the Veterans Health Administration.

Attached files

Contact

Renee Kale(Contracting Officer)

[email protected]

(412) 822-3757

Key dates

Opened
5/18/2026
Questions due
5/22/2026
Closes
6/17/2026
Duration
1095 days

Last updated

Details

Type
Request for Quotation
Industry
Healthcare and Medical Services
NAICS
541380
Solicitation №
36C24E26Q0040

Budget estimate

$100,000 – $500,000

The budget for this contract is likely to be in the range of $100,000 to $500,000, based on the fact that it is a quotation for a specific product or service related to blood assays for Alzheimer's disease. The actual budget will depend on the specific requirements and pricing of the contract. Factors that may influence the likely payment range include the scope of work, the experience and qualifications of the contractor, and the budget of the Veterans Health Administration.

AI estimate from the solicitation

Similar opportunities

Matched by Bid Banana AI™

Bid Banana · 1.6M+ bids and awards 🍌

You found this one too late. Don't find the next one too late.

Bid Banana searches open government bids across all 50 states, updated daily. Save a search once and we email you your new matches, daily or weekly, while there is still time to win them.

1.6M+
bids & awards
All 50
states
4,000+
agencies
Start your 7-day free trial

Plans from $49.99/month. Cancel anytime, no setup fees.

Built by The Bid Lab, answering RFPs since 2017.

U.S. National Institutes of Health·United States of America

Top match · 72%

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Closes 11/5/2027Opened 11/15/2021

U.S. National Institutes of Health·United States of America

71% match

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Closes 6/17/2027Opened 8/13/2026

U.S. National Institutes of Health·United States of America

70% match

Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

Closes 5/7/2028Opened 12/30/2024

U.S. National Institutes of Health·United States of America

69% match

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)

Closes 1/7/2028Opened 10/28/2024

U.S. Department Of Veterans Affairs·Texas

68% match

6550--Blood Bank Reagents

Closes 11/5/2026Opened 10/28/2026

U.S. Department Of Veterans Affairs·Illinois

68% match

Q301--Blood Donor Panel Testing for Captain James A. Lovell Federal Health Care Center (FHCC)

Closes 11/3/2026Opened 10/27/2026

U.S. National Institutes of Health·United States of America

68% match

Functional Target Validation for Alzheimer's Disease-Related Dementias

Closes 11/5/2026Opened 3/11/2026

U.S. National Institutes of Health·United States of America

67% match

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Closes 11/9/2026Opened 2/12/2026

U.S. Department Of Defense·Maryland

67% match

RFI Alzheimer’s Research Program (AZRP) Public

Closes 12/4/2026Opened 10/27/2026

U.S. National Institutes of Health·United States of America

67% match

Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)

Closes 3/1/2027Opened 1/8/2026

U.S. National Institutes of Health·United States of America

67% match

The NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS)

Closes 10/31/2026Opened 5/18/2026

U.S. National Institutes of Health·United States of America

67% match

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

Closes 11/10/2026Opened 8/28/2025

U.S. National Institutes of Health·United States of America

67% match

NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 Independent Clinical Trial Not Allowed)

Closes 5/26/2027Opened 6/9/2025

U.S. National Institutes of Health·United States of America

66% match

ancient DNA for Modern Genomics (aDMG) Research Projects (U01 Clinical Trials Not Allowed)

Closes 1/31/2028Opened 6/2/2026

Iowa State University·Iowa

66% match

Blood Spot and Dried Urine Testing

Closes 11/6/2026Opened 10/23/2026

U.S. National Institutes of Health·United States of America

66% match

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Closes 2/7/2027Opened 12/8/2025

U.S. National Institutes of Health·United States of America

65% match

New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)

Closes 5/7/2027Opened 3/19/2024

U.S. Department Of Health And Human Services·Maryland

65% match

NIA:Non-Competitive Combined Synopsis/Solicitation

Closes 11/6/2026Opened 10/28/2026

U.S. Food and Drug Administration·United States of America

65% match

Studies Addressing Rare Neurodegenerative Diseases including ALS

Rolling / TBD closeOpened 8/14/2024

U.S. National Institutes of Health·United States of America

65% match

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

Closes 5/24/2027Opened 9/23/2026

U.S. National Institutes of Health·United States of America

65% match

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

Closes 9/10/2027Opened 12/13/2024

U.S. National Institutes of Health·United States of America

65% match

NIDA Avenir Program: Fundamental Mechanistic Research in Addiction Science

Closes 5/25/2027Opened 9/10/2026

U.S. National Institutes of Health·United States of America

65% match

Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)

Closes 11/23/2026Opened 5/28/2025

U.S. National Institutes of Health·United States of America

65% match

New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)

Closes 5/7/2027Opened 3/19/2024

U.S. National Institutes of Health·United States of America

65% match

Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)

Closes 2/9/2027Opened 8/20/2026